GlassScriptPhysician profile
Marcus Nielson
NPI 1376257170
$2,364.83
in general payments reported to CMS, 2019-2025
18 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $950 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $545.69 | 2024-2025 | |
| Axsome Therapeutics, INC. | $400.46 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.15 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $201.55 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $183.50 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $182.54 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $146.88 | 2024-2025 | Lybalvi |
| Corium, LLC | $89.38 | 2024-2025 | Azstarys |
| Lundbeck LLC | $84.86 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $69.31 | 2024-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $58.53 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $50.33 | 2024 | Ingrezza |
| Vertical Pharmaceuticals, LLC | $40.43 | 2024-2025 | Relexxii |
| Biogen, INC. | $29.27 | 2025 | Zurzuvae |
| Livanova USA, INC. | $20.16 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.56 | 2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $15.44 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $13.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Nielson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.